Equities

Argenica Therapeutics Ltd

Argenica Therapeutics Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.75
  • Today's Change-0.04 / -5.06%
  • Shares traded182.25k
  • 1 Year change+87.50%
  • Beta--
Data delayed at least 20 minutes, as of Sep 20 2024 06:51 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Argenica Therapeutics Limited is an Australia-based clinical drug development company. The Company is focused on developing therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE).

  • Revenue in AUD (TTM)192.09k
  • Net income in AUD-5.48m
  • Incorporated2019
  • Employees--
  • Location
    Argenica Therapeutics Ltd4/117 BroadwayNEDLANDS 6009AustraliaAUS
  • Phone+61 89329-3396
  • Websitehttps://argenica.com.au/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
IDT Australia Limited14.12m-5.41m51.58m156.00--1.80--3.65-0.0154-0.01540.04040.06670.47341.842.62---18.15-9.77-22.59-11.6180.1184.61-38.33-23.121.12-50.050.1601--100.813.0936.30---10.39--
Inoviq Ltd791.70k-6.55m54.37m85.00--2.57--68.67-0.0709-0.07090.00860.18940.03664.540.6418---30.33-44.62-32.64-47.5589.77---827.88-1,928.527.06--0.0198--5.29146.3326.92------
Anteotech Ltd514.89k-8.88m54.77m40.00--10.23--106.38-0.0039-0.00390.00020.00220.0699--2.55---120.47-75.24-159.35-84.74-----1,724.74-1,444.66----0.3055--26.8527.9329.82--68.39--
Neurotech International Ltd3.34m-5.07m64.55m----5.39--19.35-0.0054-0.00540.00370.01170.38070.0011.59---57.86-134.56-63.92-163.66100.00---151.98-462.3838.81--0.00--165.9867.3934.94------
Paradigm Biopharmaceuticals Ltd6.52m-58.65m82.31m----3.46--12.62-0.1875-0.18750.01860.0680.138--1.10---124.19-52.89-150.28-58.0699.86---899.60-543.63---961.470.006---23.2214.97-12.99------
Actinogen Medical Ltd291.02k-13.04m84.09m----4.28--288.94-0.0061-0.00610.00010.00720.0159--0.0433---71.44-48.56-78.20-51.97-----4,482.26-5,188.44---163.100.0159---20.637.31-21.32------
Proteomics International LaboratoriesLtd1.41m-6.38m85.15m----9.04--60.41-0.0507-0.05070.01120.07190.1346--6.45---61.88-60.46-67.65-69.49-----459.82-290.18---208.630.0331---4.24-1.45-3.23--60.39--
Percheron Therapeutics Ltd615.48k-11.92m88.35m8.00--9.44--143.55-0.0135-0.01350.00070.01040.045--0.2912---87.09-75.92-122.82-89.91-----1,936.57-4,028.81---1,956.650.0042--59.9056.21-4.74------
Argenica Therapeutics Ltd192.09k-5.48m100.44m----7.00--522.85-0.0518-0.05180.00190.11280.0148--0.7326---42.28---50.70-------2,852.56-----21,829.870.00--214.90---13.80------
LTR Pharma Ltd49.00k-6.95m150.08m----83.92--3,062.79-0.0499-0.04990.00040.0211---------------------14,192.84-----414.020.00-------378.00------
Data as of Sep 20 2024. Currency figures normalised to Argenica Therapeutics Ltd's reporting currency: Australian Dollar AUD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.